Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-355 pembrolizumab plus chemotherapy in previously untreated recurrent inoperable or metastatic triple-negative breast cancer
NL-OMON47725Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Feb 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pembrolizumab in triple-negative breast cancer (TNBC) and breast cancer (5 arms), sponsored by Merck & Co. Started Feb 2017; status: active, not recruiting.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on NL-OMON47725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47725.